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Targeting of Renal Cell Carcinoma W ith  Iodine-131 
Labeled Chimeric M onoclonal Antibody G250
By MarHjn G. Steffens, Otto C. Boerman, Jeanette C. Oosterwijk-Wakka, Gosse O.N. Oosterhof, J. Alfred Witjes,
Emile B. Koenders, Wim J.G. Oyen, W il C.A.M. Buijs, Frans M.J. Debruyne, Frans H.M. Corstens,
and Egberï Oosterwijk
Purpose: Pharmacokinetics, biodistribution, immu- 
nogenicity, and imaging characteristics of iodine 131 
(,31l)-labeled chimeric monoclonal antibody (mAb) G250  
(cG250) were studied in patients with renal cell carci­
noma (RCC) to determine the therapeutic potential of this 
antibody.
Patients and Methods: Sixteen patients with RCC re­
ceived a single intravenous (IV) infusion of 6 mCi 131l- 
labeled cG250. Five protein dose levels were investi­
gated (2 to 50 mg). Planar scintigraphic images were 
acquired, and normal tissue biopsies and tumor samples 
were obtained at surgery (7 days postinjection). The im- 
munogenicity of cG250 was investigated using a sand­
wich enzyme*’Kinked immunosorbent assay (ELISA) and 
dosimetric analysis was performed.
Results: In all patients with antigen-positive tumors 
(n = 13)^ the primary tumors and all known metastases 
were clearly visualized. Overall uptake, expressed as 
the percentage of the injected dose (%ID), in the primary 
tumors ranged from 2.4  to 9.0. Focally, 131l-cG250 up-
R
ENAL CELL CARCINOMA (RCC) is the most 
common malignant disease of the adult kidney, and 
accounts for 80% to 90% of all primary kidney neo­
plasms.1 Approximately 30% to 40% of all patients pres­
ent with metastatic disease at the time of diagnosis,2 The 
treatment of choice for RCC patients without clinical 
apparent metastatic disease is radical nephrectomy. How­
ever, about one third of these patients develop metastases 
after surgery, usually within 1 year. For these patients, 
as well as for patients with advanced disease, the 5-year 
survival rate is less than 10% and the median survival 
time is less than 2 years.2 Given such a poor prognosis, 
there is need for a more effective treatment for RCC 
patients following radical nephrectomy.
Since the development of hybridoma technology by 
Köhler and Milstein,3 therapeutic approaches using 
monoclonal antibodies (mAbs) have been investigated in­
tensely. Nevertheless, their therapeutic promise still needs 
fulfillment. In patients with primary RCC, excellent tumor 
targeting of iodine 131 (131I)-labeled murine mAb G250 
(mG250) was shown.4 In a subsequent activity dose-esca- 
lation study with 13,I-mG250 in patients with metastasized 
RCC, a few minor responses were observed.5 Although 
mG250 seemed a suitable vehicle for radioimmunother­
apy, the occurrence of human antimouse antibodies 
(HAMA) in all patients studied hampered the use of 
mG250 for multiple-treatment radioimmunotherapy, 
which was possibly necessary to obtain durable re­
sponses. To minimize the occurrence of HAMA, a chi-
take as high as 0.52%  ID /g  was observed. However, 
intratumoral uptake was highly heterogeneous. 1311- 
cG250 uptake in nontumorous tissues remained low. Do­
simetric analysis showed that up to .48 Gy/m Ci was 
guided to the primary tumors. Selected “ hot areas"  
within these tumors received up to .72 Gy/m Ci. A bone 
metastasis received .23 Gy/mCi and regional lymph 
node metastases received .20 Gy/m Ci. Minimal human 
antichimeric antibody (HACA) levels were detected in 
two of 16 patients.
Conclusion: 131l-cG250 tumor uptake is among the 
highest reported in clinical studies with antitumor anti­
bodies in solid tumors. Since tumor-sterilizing levels may 
be guided to the tumor when high doses 131l-cG250 are 
administered (>  100 mCi) and cG250 appears to be im- 
munosilent, cG250 is a promising vehicle for radioimmu­
notherapy in RCC.
J Clin Oncof 15:1529“ 1537. © 1997 by American So­
ciety of Clinical Oncology.
*
merized version of mAb G250 (cG250) has been devel­
oped. In this study, we report on a clinical phase I protein 
dose-escalation trial with 13,I-labeled cG250 performed 
to determine the safety of a single intravenous (IV) infu­
sion. The in vivo behavior in terms of pharmacokinetics, 
biodistribution, immunogenicity, and imaging character­
istics of this chimerized antibody as compared with its 
murine progenitor was studied in patients with primary 
RCC. In addition, dosimetry was performed to estimate 
the radiation absorbed dose that was guided to RCC le­
sions and organs at risk to determine the therapeutic po­
tential of 13,I-cG250.
PATIENTS AND METHODS
Patient Characteristics
Sixteen patients with a clinical diagnosis of primary RCC were 
studied: 10 men, age 46 to 80 years (mean, 59), and six women,
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Table 1. Patient Characteristics
Patient No. Age, years Sex
cG250 Dose
(mg)
1311 Dose 
(mCi)
Tumor-ceil
Type
G250
Expression
1 52 F 2 6.0 Clear +  +
2 46 M 2 6.0 Clear +  4-
3 58 M 2 6,0 Clear -f
4 65 M 5 6.0 Clear + +
5 53 M 5 6.0 Basophilic —
6 74 F 5 6.0 Granular —
7 40 F 10 6.0 Clear + +
8 56 M 10 6.0 Clear + +
9 70 F 10 6.0 Clear + +
10 58 F 25 6.0 Oncocytic —
11 52 M 25 6.0 Clear + +
12 59 M 25 6.0 Clear +
13 80 M 50 6.0 Clear -f-
14 69 F 50 6.0 Clear + +
15 67 M 50 6.0 Clear +  +
16* 66 M 5 6.0 Clear + + +
Abbreviations: F, female; M, male; + + + ,  > 95% tumor cells antigen- 
positive; + + , 50-95% tumor cells antigen-positive; + , 5-50% tumor cells 
antigen-positive; —, <  5% tumor cells antigen-positive.
* Extra patient at 5-mg dose level.
age 40 to 74 years (mean, 61), All patients underwent a radical 
tumor nephrectomy 1 week after infusion of the antibody as part of 
their treatment plan. Patient characteristics are listed in Table 1. The 
study protocol and consent forms were approved by the institutional 
review board (IRB) of the University Hospital Nijmegen. Before 
participating, all patients reviewed and signed informed consent,
mAb cG250
The generation, characteristics, and reactivity of mAb mG250 
have been described earlier.6 In summary, mAb G250 is reactive 
with the antigen G250, expressed in all clear cell RCCs and the 
majority of non-clear cell RCCs. Expression in normal organs is 
restricted to the gastric mucosal cells and the larger bile ducts. mAb 
cG250 immunoglobulin G1 (IgGl) has been produced by DNA re­
combinant technology as described by Velders et al.7 Essentially, 
the constant regions of heavy and light chains of mAb mG250 were 
substituted by their human analogs.
The cG250 antigen-binding specificity was studied in vitro in a 
competitive binding assay. Briefly, I25I-labeled mG250 was incu­
bated with 106 G25O-expressing RC-SK-52 cells (a human RCC 
cell line kindly provided by Dr L.J. Old, Memorial Sloan-Kettering 
Cancer Center, New York, NY) and increasing amounts of either 
unlabeled cG250 or unlabeled mG250, Cells were incubated for 4 
hours at room temperature. Subsequently, the cell suspension was 
centrifuged and the activity associated with the cell pellet measured 
in a gamma counter (1480 Wizard 3"; Wallac Oy, Turku, Finland).
The affinity constant (K„) of cG250 was determined in a Scatchard 
analysis on RC-SK-52 cells as described previously.8
Radiolabeling and Quality Control
Sterile vials with purified and pyrogen-free, clinical grade cG250 
were generously provided by Centocor Europe B V, Leiden, the Neth­
erlands. mAb cG250 was labeled according to the Iodogen (Pierce 
Chemical Co, Rockford, IL) method.9 Briefly, 0.4 mL cG250 (5 mg/ 
mL) and 100 fiL 0.5-mol/L sodium phosphate (pH 7.2) were added 
to an iodogen-coated tube (50 fig). Subsequently, 10 mCi sodium
(Na)i3!I (Nordion, Fleur us, Belgium) was added. After 10 to 15 
minutes of incubation at room temperature, the reaction mixture was 
applied on a PD 10 column (Pharmacia, Woerden, the Netherlands) 
and eluted with phosphate-buffered Saline (PBS). The first activity 
peak eluted from the PD 10 column was collected and cold cG250 
was added to obtain the desired amount cG250 protein labeled with 
6 mCi 1311. Instant thin-layer chromatography (ITLC) was used to 
determine the presence of free 13'1 and the immunoreactive fraction 
of each preparation was determined on freshly trypsinized SK-RC- 
52 cells as described previously.8
Study Design
Before the antibody injection, the medical history of each patient 
was taken and a physical examination was performed. To block 13lI 
uptake in the thyroid, patients received 100 mg potassium iodide 
two times daily and 200 mg potassium perchlorate four times daily, 
starting 24 hours before administration of the radiolabeled antibody. 
This regimen was continued until surgery. Five protein dose levels 
of cG250 were investigated (2, 5, 10, 25, and 50 mg) with at least 
three patients per dose level.13lI-cG250 in 0.9% sodium chloride 
(NaCl) (total volume, 10 to 20 mL) was administered IV over a 
20-minute period. Vital signs were measured frequently and blood 
samples were drawn just before the antibody administration and at 
later time points until surgery. Whole-body images were recorded
1, 24, 48, 96, or 120 and 144 or 168 hours postinjection using a 
dual-headed gamma camera (Multispect 2; Siemens Inc, Hoffman 
Estates, IL) equipped with a high-energy collimator. At surgery (1 
week postinjection), a tumor nephrectomy was performed and biop­
sies of normal tissue (skin, fat, muscle, peritoneum, and liver) were 
obtained. All primary tumors were cut in slices of 1-cm thickness. 
The slices were imaged directly on a single-head gamma camera 
(Orbiter; Siemens Inc) equipped with a high-energy collimator. Us­
ing the images, tumor samples (1 cm3), including high and low 
uptake areas, were selected from a tumor slice. Tissues were weighed 
and the 1311 content was measured in a gamma counter. l3,I-cG250 
blood levels and tumor and normal tissue uptake were expressed as 
the percentage of the injected dose per gram of tissue (%ID/g). The 
half-life of disappearance from the blood was calculated by nonlinear 
least-square regression analysis.
Immuno h is to c hem is tty
Antigen expression was determined by immunohistochemistry on 
a number of selected tumor samples. Briefly, 4-fim cryostat sections 
of snap-frozen tumor biopsies were acetone-fixed, washed, incubated 
for 1 hour at room temperature with 100 ¡XL of 10 /xg/mL mAb 
mG250, washed, reacted with peroxidase-labeled rabbit antimouse 
Ig (RAMPO; DAKO, Carpentina, CA), washed, and developed with
3-3'-diaminobenzidine/0.03% hydrogen peroxide (H20 2). Antigen 
expression was scored as follows: less than 5% cells positive; -b, 
5% to 50% cells positive; ++, 50% to 95% cells positive; and + + -1-, 
greater than 95% cells positive.
Determination of Human Antichimeric Antibody 
Responses
The immunogenicity of cG250 was investigated in serum samples 
of all patients obtained before and 1, 3, 6 , and 12 weeks after 
infusion. A sandwich enzyme-linked immunosorbent assay (ELISA) 
was developed in which cG250 was used as catcher antibody and 
biodnylated cG250 as tracer antibody. Biotinylation of cG250 was 
performed according to the manufacturer's instructions (Pierce Eu­
rope, Oud Beijerland, the Netherlands). Wells of 96-well microtiter
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Fig 1. Blood clearance of 131l- 
cG 250  in RCC patients. Blood 
was collected from 16 patients 
{at least 3 patients per dose 
level} at time 0 (5 minutes postin­
jection) through day 7. Each 
curve represents mean blood 1311 
levels (expressed as %ID/g  
blood) in patients at the different 
dose levels.
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plates (Costar, Cambridge, MA) were coated with cG250 by incuba­
tion overnight at 4°C with 100 ¡iL of 2.5-fig/mL cG250. After 
blocking with 1% bovine serum albumin (BSA) in PBS (1 hour at 
37°C), wells were rinsed with PBS/1 % BSA (three times), serial 
dilutions of patient sera were added (100 //L/well, starting undiluted, 
i hour at 37°C), rinsed (PBS/1% BSA, three times), and incubated 
with 100 pL of 1.25-^g/mL biotinylated cG250 (1 hour at 37°C). 
After another wash (PBS/1 % BSA, three times), wells were incu­
bated with streptavidin-biotinylated horseradish peroxidase complex 
for 30 minutes at 37°C (Amersham, Little Chalfond, United King­
dom). Wells were washed (PBS/1 % BSA, three times) and developed 
with 3,3\5,5'-tetramethylbenzidine/H20 2 (100 ¿¿L, 20 minutes at 
room temperature). The reaction was stopped by adding 100 jiL 2.5- 
mol/L sulfuric acid (H2S04). Optical density was measured at 450 
am. Proven human antimouse antibody (HAMA)-positive sera from 
patients who participated in previous trials with mG250 were used 
as positive controls (a kind gift of Dr N.H. Bander, New York 
Hospital, New York, NY). Serial dilutions of antiidiotype antibody 
NUH-82 IgG l10 were used to obtain a standard curve. The detection 
limit of the assay was 25 ng NUH-82/mL.
To define further the epitopes of the cG250 IgGl molecule against 
which a human anti chimeric antibody (HACA) response might be 
directed, sera that were positive in the sandwich ELISA as described 
earlier were investigated in two similar ELIS As, as follows; (1) 
mG250 IgGl as catcher/tracer antibody to determine any response 
against the murine part of cG250, and (2) chimeric MOvl8 (a mAb 
reactive with an ovarian cancer-associated antigen) with the same 
human constant regions as cG250 was used as catcher antibody and 
biotinylated cG250 as tracer antibody to detect reactivity directed 
against the human part of cG250.
Dosimetiy
Dosimetric analysis was performed in 10 patients (two patients 
at each dose level). The conjugated views counting technique for 
the whole-body images was used to quantitate 13,I-cG250 uptake in 
selected organs.11 Briefly, regions of interest (ROI) over the tumor,
whole body, chest, total abdomen, pelvis, liver, spleen, and extremi­
ties were drawn on anterior and posterior view images recorded at all 
five time points. The differences in attenuation between the thorax, 
extremities, and abdomen were determined using a 1311 transmission 
flood source. The geometric mean of anterior and posterior counts 
was calculated after correction for differences in attenuation. After 
background subtraction and correction for physical decay, absolute 
retention of activity in a ROI was calculated via comparison with 
the activity of the total-body scintigram directly after infusion. Data 
were expressed as a percentage of the total injected dose (%ID). 
Radiation-absorbed doses to the tumor and to organs of interest were 
calculated with the MIRDOSE3 program. 12
RESULTS
Affinity, Immiuio re activity, Radiolabeling, and Quality 
Con tro I
To evaluate whether chimerization of mAb G250 had 
affected the binding characteristics of the antibody, com­
petitive binding assays were performed. Competition 
analysis showed that unlabeled cG250 was at least equally 
effective in displacing L25I-mG250 as unlabeled mG250. 
The IC30 of mG250 was 1,100 pmol/L and the inhibition 
concentration5o (IQo) of cG250 was 700 pmoi/L (data 
not shown). The affinity constants (K J of both mG250 
and cG250 as determined in a Scatchard analysis were 
identical with a Ka = 4  X 109 mol/L'1.
The efficiency of the radioiodination reaction, ie, the per­
centage of 131I added to die reaction that was bound to the 
antibody, varied between 65% and 80%. After PD 10 elu­
tion, ITLC showed that greater tiian 99% of the pooled 
radioactivity was protein-bound (release criterium > 95%).
The mean immunoreactive fraction of the mI-cG250
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Fig 2. Whole-body scans recorded 7 days postinjecHon. (A) patient no. 2, 2-mg dose; (B) patient no. 9, 10-mg dose. Images were printed 
at the same grey scale. Arrows: primary iumors in both patients. Note difference in relative liver uptake between the 2 dose levels. Arrowhead: 
metastasis of the ischiadic bone. Ant, anterior view; Post/ posterior view.
preparations was 95% ± 5%. In two patients, the imrnu- 
noreactive fraction of plasma I31I activity was monitored 
up to 1 week postinjection and at least 80% of the circulat­
ing 13'1 activity was shown to be immunoreactive for the 
investigated period (0 to 7 days postinjection).
Clinical Observations
The injection of the radiolabeled antibody was tolerated 
well by all patients and no side effects were seen. No 
significant changes in vital signs, hematologic, or blood 
chemistry parameters were observed.
Pharmacokinetics
The mean blood clearance curves from patients with 
G250-positive tumors at the various dose levels are shown
in Fig 1. Curves fitted a two-comp ailment model. The 
half-life of the distribution phase (t1/2a:) was similar at all 
protein dose levels (t 1/2a = 3.8 ± 2.0 hours). In contrast, 
the half-life of the elimination phase (t1/2/3) differed sig­
nificantly between the 2-mg and the higher protein dose 
levels. At the 2 mg protein dose level, tmp was signifi­
cantly lower (ti/2)3 = 39.6 ± 9.6 hours) as compared with 
the other, higher protein dose levels (UnP ~ 68.5 ± 13.5 
hours) (P < .005). Mean overall cumulative excretion in 
the urine in 7 days was 59.9% ± 12.9% ID, which indi­
cates that the primary route of radiolabel excretion was 
via the kidneys.
Imaging
Excellent visualization of primary tumors was obtained 
in all 13 patients with G250 antigen-positive tumors. In
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Ant. Post.
Fig 3. Whole-body scan (patient no. 8, 10«mg dose) recorded 7 
days postinjection. Primary tumor (arrows) and multiple regional 
lymph node metastases (arrowheads) are indicated. These lymph 
nodes received a dose of .20 Gy/mCi. A background region drawn 
over the aorta was used for background correction.
general, tumors lesions were visualized from 1 day post­
injection onwards. Due to the background clearance of 
I31I'CG250, image quality improved with time. In some 
cases studied at the lower protein dose levels (2 and 
5 mg)} bowel activity complicated interpretation of the 
images. All metastatic lesions (five) as identified by ultra­
sound, computed tomography, or x-ray, were visualized: 
one bone (patient no. 2, Fig 2), one pulmonary (patient 
no. 4), one brain (patient no. 12), one vaginal (patient no.
9), and multiple regional lymph node metastases (patient 
no. 8, Fig 3).
At higher protein dose levels (25 and 50 mg), tumor 
accumulation was less pronounced, and as a consequence, 
tumor images were less clear as compared with images 
at the lower protein dose levels. Nevertheless, tumors 
were still well delineated at the higher protein dose levels.
As was observed with mG250,4 liver uptake was more 
pronounced at the 2-mg dose level as compared with the 
higher protein dose levels (Fig 2).
Bio distribution
Extensive tumor sampling and sampling of selected 
normal tissues 8 days postinjection was performed to de­
termine the absolute uptake of l3!I-cG250 (Table 2). The 
overall uptake in the tumorous kidneys (including the 
remaining normal kidney tissue and perirenal fat) ranged 
from 2.4% to 9.0% ID. Most of these tumorous kidneys 
were large, with a weight greater than 1,000 g (range, 
300 to 1,700 g), and some contained large areas with 
extensive necrosis. Therefore, 1-cm3 samples were taken 
from viable tumor areas and the radioactivity in each 
sample was determined separately. In most antigen-posi­
tive tumors, considerable differences in regional tumor 
uptake, up to two orders of magnitude, were observed
*
(Fig 4). In three tumors (patients no. 1, 9, and 16), focal 
tumor uptake was greater than 0.1% ID/g. The highest 
focal tumor uptake was found in the primary tumor of 
patient no. 16 (5-mg dose): 0.5233% ID/g. In the primary 
tumors of patients who received 25 or 50 mg cG250, 
tumor uptake was not greater than 0.0170% ID/g, while 
at the lower protein doses, higher focal uptake was found. 
Uptake in a cluster of tumor-positive lymph nodes (pa­
tient no, 8) was 0.0136% ID/g. Uptake in necrotic areas 
remained low and was not greater than 0.0015% ID/g. 
cG250 uptake in antigen-negative tumors was not greater 
than 0.0040% ID/g (range, 0.0005% to 0.0040% ID/g; 
Table 2).
Activity measurements of the liver biopsies (all patients 
with antigen-positive tumors) confirmed the enhanced 
liver uptake, as noted on the images, at the lower protein 
dose levels (0.0034% ± 0.0020% ID/g at 2-mg dose and 
0.0017% ± 0.0002% ID/g at 5-mg dose) as compared 
with the liver uptake at the higher protein dose levels 
(0,0009% ± 0.0003% ID/g). Assuming a total liver mass 
of 1,5 kg, liver uptake at the 2-mg dose accounted for 
5.1% of the total injected dose, while at the higher protein 
dose levels (10, 25, and 50 mg), liver uptake accounted 
for 1.4% of the total injected dose.
HACA Responses
In two patients (no. 7 and 8), a HACA response could 
be detected in the sera obtained at 12 weeks postinjection 
as determined by sandwich ELISA with cG250 as catcher/ 
tracer antibody. HACA responses were not detectable 
in sera obtained earlier than 12 weeks postinjection and 
HACA levels in these two patients were low, with a 
maximum equivalent of 300 ng/mL NUH-82, whereas 
the positive control sera (from patients who participated
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Table 2. Biodistribution of 131l-cG250 mAb
Patient N o ./ 
Dose
Tissues (uptake in %ID X 10 3/g)
1
RCC Samples 
2 3 4
Normal
Kidney Liver Peritoneum Fat Muscle Skin Blood
1/2 mg 342.0 102.0 80.0 0.2 5.3 4.0 2.1 0.2 0 .6 0.4
2 /2  mg 76.0 52.0 21.0 11.0 0.4 3.7 0.2 0.3 0 .2 1.6 0.4
3 /2  mg 7.0 6,0 5.0 0.5 1.3 1.1 0.2 0.5 1.2 1.2
4 /5  mg 42.0 36.0 28.0 21.0 0.9 1.8 1.7 2.4 0.5 2.0 1.3
5 /5  mg* 0.5 0,5 0.5 0.7 2.6 2.9 0.7 0.3 2.2 2.5
6 /5  mg* 4.0 2.0 1.5 0.9 2.5 2.0 5.2 1.3 2.4 4.2
7 /10  mg 28.0 27.0 26.0 23,0 3.6 0.9 1.5 0.2 0.8 1.7 3.9
8 /10  mg 23.0 22.0 21.0 18.0 1.4 1.2 3.7 0.2 0.2 1.2 2.7
9 /10  mg 169.0 131.0 130.0 12.0 0 .6 1.1 1.7 0.2 0.4 1.8 3.9
10/25 mg* 1.7 1.5 2.2 1.9 1.5 0.8 1.3 2.6 7.7
11/25 mg 60.2 30.3 17.2 14.0 1.0 0.9 0.9 0.3 0.3 1,4 3.0
12/25 mg 3.6 3.1 2.6 2.3 0.7 0.4 1.1 0.4 0.5 0.9 2.9
13/50 mg 6,3 5.7 4.8 4,6 1.2 1.1 1.6 0.2 0.4 1.5 4.7
14/50 mg 12.0 12.0 11.9 11.3 1.6 1.2 2 .5 0 .6 0.8 2.9 6.6
15/50 mg 9.9 9.1 8.2 7.7 0 .7 0.6 1.1 0.4 0.4 1.3 4.3
16/5 mgt 523.3 393.2 324.7 96.1 0 .8 1.5 0.9 0.3 0,2 1.1 2.8
*Patients with an antigen-negative tumor. 
fExtra patient at 5-mg dose level.
in trials with mG250) showed HAMA levels up to 36,000 
ng/mL NUH-82. Follow-up serum samples, drawn at 20 
weeks postinjection, showed that the HACA responses in 
these two patients did not increase. Further analysis of 
these HACA responses with the ELIS As using (1) murine 
G250 as catcher/tracer antibody and (2) chimeric MOvl8 
as catcher/cG250 as tracer antibody showed that these 
responses were not directed against the human part of the
cG250 IgG molecule.
In the preinjection serum sample of patient no. 9, pre­
existing antibodies reactive with both mG250 and cG250 
were detected (300 ng NUH-82/mL).
Dosimetiy
Dosimetric analysis performed in 10 patients (two pa­
tients per dose level) showed that the radiation-absorbed 
dose to the G250-positive primary tumors ranged from 
.06 (patient no. 1, 2-mg dose) to .48 Gy/mCi (patient no.
G250 expression
+ +  + +  +  + +  + + 4 ++ ++ ++ ++ + + ++ ++
o>
Q
1
0.1 =
0.01 r
0.001 =
0.0001
1 2 3 4 16 5 6 7 8 9 10 11 12 13 14 15
patient #
Fig 4. Scatterplot of m l- 
cG250 uptake in tumor samples 
(± 1 cm3) obtained from the pri­
mary tumors. Tumor uptake var­
ied greatly not only between dif­
ferent tumors, but also within the 
same tumor, lmmunohistochemi- 
cal staining indicated that tu­
mors from patients no. 5, 6, and 
10 were G250-negative (O) .
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Table 3. Dosimetric Analysis
Patient No./Dose
Radiation-Absorbed Dose Estimates (Gy/mCi)
Whole Tumor ROI Primary Tumor Metastases Liver Thyroid Bons Marrow
1 / 2  mg .06 .42 .06 ,008
2 / 2  mg .09 .28 .23 (bone) .06 .17 .007
4 / 5  mg .10 .19 .03 .34 .009
1 6 /5  mg .48 .72 .03 .13 .on
8 /1 0  mg .15 .31 ,20 (lymph nodes) .04 .13 .010
9 /1 0  mg .10 .53 .04 (vaginal) .04 .18 .013
1 1 /2 5  mg .09 .13 .05 .26 .010
1 2 /2 5  mg .07 .09 .01 (brain) .03 .11 .011
1 4 /5 0  mg .15 .18 .05 .12 .018
1 5 /5 0  mg .12 .16 .02 .09 .013
Overall .04 ± .01 .17 ±  .08 .011 ±  .003
Abbreviation: ROI, region of interest.
16, 5-mg dose). As considerable tumor heterogeneity was 
observed, which was partially a reflection of tumor necro­
sis, radiation-absorbed dose estimates were also calcu­
lated for selected “hot areas” within these primary tu­
mors. This analysis showed that considerably higher 
radiation-absorbed doses were guided to these areas (Ta­
ble 3). The highest amount of radioactivity was delivered 
to a tumor thrombus, which received .72 Gy/ mCi (patient 
no. 16, 5-mg dose, Fig 5). More importantly, dosimetric 
analysis of metastatic lesions showed that a bone metasta­
sis received .23 Gy/mCi (patient no. 2, 2-rng dose) and 
regional lymph node metastases received .20 Gy/mCi (pa­
tient no. 8, 10~mg dose).
Calculation of the mean radiation-absorbed dose to or­
gans at risk indicated that .17 ± .08 Gy/mCi was delivered 
to the thyroid, the liver received .04 ± .01 Gy/mCi, and 
the bone marrow received .011 ± .003 Gy/mCi.
DISCUSSION
A phase I protein dose-escalation study was performed 
to determine the pharmacokinetics, toxicity, immunogenic- 
ity, and imaging characteristics of l3lI-labeled mAb cG250 
in patients with RCC. Previous studies have indicated that 
mAb mG250 may have considerable therapeutic potential 
as a vehicle for radioirmmmotherapy 4,5 provided the strong 
HAMA responses can be circumvented. Multiple doses are 
probably needed to produce any lasting responses in radio­
immunotherapy. Chimerization resulted in a major decrease 
of the immunogenicity of this antibody: minimal HACA 
responses were detected in only two patients as determined 
by cG250 sandwich ELISA. No measurable immune re­
sponses were detected against the human part of cG250. 
The minimal, presumably clinically nonrelevant HACA re­
sponses, observed in two of 16 patients, illustrate the highly 
reduced immunogenicity of cG250 as compared with its 
murine progenitor. Therefore, multiple treatments with
cG250 seem feasible. These observations are in accordance 
with (lie results of other studies: Meredith et al13 showed 
that chimerization of mAb 17-1A highly reduced the immu­
nogenicity and Buist et al14 found similar results with chime­
ric mAb MOvl.8.
The in vitro binding characteristics of cG250 were similar 
to those of mG250, which demonstrates that chimerization 
of the antibody did not affect specificity, affinity, or avidity. 
In general, die in vivo behavior, including the half-life
(tI«/?), of cG250 was comparable to mG250 ( t|aft cG250 
68.5 hours v t\n(3 mG250 47 hours). The first chimerized 
antibodies, eg, chimeric mAb 17-1 A13 and chimeric mAb 
B72.3,15 showed much longer half-lives in patients than their 
murine progenitors, which resulted in relatively poor tumor/ 
nontumor ratios, considered a disadvantage in radioimmu­
notherapy. However, other chimerized antibodies, eg, chi­
meric mAb MOvI8,16 chimeric anticarcinoembryonic anti­
gen (anti-CEA) antibodies,17 and chimeric mAb LL2,1S have 
shown half-lives similar to their murine counterpart, as was 
observed for mAb cG250.
Antigen-mediated tumor uptake of ,3lI-cG250 was 
demonstrated by the difference in uptake between anti­
gen-positive versus antigen-negative tumors: uptake in 
samples of antigen-negative tumors (7 days postinjection) 
was not greater than 0.0040% ID/g (blood 7 days postin­
jection, 0.0042% ID/g), while uptake in antigen-positive 
tumors was as high as 0.5233% ID/g (blood, 0.0028% 
ID/g). Extensive sampling of the primary tumors showed 
that regional differences in tumor uptake were as high as 
two orders of magnitude. This observed heterogeneity 
was much more pronounced at the 2-, 5-, and 10-mg dose 
levels as compared with the 25- and 50-mg dose levels. 
In addition, tumor uptake greater than 0.1% ID/g was 
observed only at the 2-, 5-, and 10-ing dose levels, while 
maximum uptake at the 25- and 50-mg dose levels was 
0.0170% ID/g and 0.0120% ID/g, respectively. These ob-
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Fig 5. Whole-body scan (patient no. 16, 2-mg dose) recorded 7 
days postinjection. Arrows: primary tumor; arrowheads: tumor 
thrombus extending into the caval vein. The primary tumor (without 
the tumor thrombus) received a dose of .48 Gy/m Ci, and the tumor 
thrombus received a dose of .72 Gy/m Ci.
servations suggest a saturation of accessible G250 epi­
topes in the tumor at the higher protein doses. In the study 
with mG250, a similar relative decrease in tumor uptake 
with increasing protein dose was observed.4 In contrast, 
in investigations with other anti tumor antibodies, doses 
of 10 mg/kg or greater have been administered without 
any indication of tumor saturation. 1CJ,2°
Saturable, anti gen-mediated liver uptake was observed 
with cG250, similar to mG250.4 This liver uptake is in 
accordance with the known antigen expression on the 
larger bile ducts.6 Assuming a liver weight of 1,500 g, 
mean liver uptake at the 2-mg dose level accounted for 
5.1 % of the total injected dose, while at the higher protein 
closes (10, 25, and 50 mg) mean liver uptake accounted
for 1.4% of the total injected dose. At the 2-mg protein 
dose level, blood clearance was faster as compared with 
the other protein dose levels. This might be the result of 
enhanced hepatic uptake at this lower protein dose level, 
since the hepatic compartment absorbed a relatively high 
amount of cG250 at 2 mg protein as compared with higher 
protein dose levels. Furthermore, higher excretion of 13ll 
in the bile as a result from this hepatic uptake may also 
explain the observed bowel activity at the lower protein 
dose levels.
All antigen-positive primary tumors, as well as all met­
astatic lesions, as identified by conventional imaging 
techniques, were visualized. Bander et al21 reported 90% 
successful imaging of primary RCC sites with l31I- 
mG250. Additionally, occult lesions, confirmed at surgery 
were visualized. In our study, no additional lesions were 
detected. Larger studies are needed to evaluate the diag­
nostic potential of mAb G250 as an imaging agent.
Radioimmunotherapy is most likely to be effective in 
metastasized patients with a relatively low tumor burden. 
In RCC patients with recurrent or metastasized disease, 
radioimmunotherapy might be applied as a second-line 
therapeutic modality, since no other effective therapy is 
available. Dosimetric analyses indicated that radiation- 
absorbed doses ranging from .06 to .48 Gy/mCi were 
guided to the primary tumors. More importantly, a num­
ber of regional lymph node metastases received .20 Gy/ 
mCi and a bone metastasis received .23 Gy/mCi. In solid 
tumors, responses of radioimmunotherapy can be ex- 
pected when radiation-absorbed doses greater than 50 Gy 
are delivered to the tumor lesions,22'24 For bone marrow,
2 Gy is considered to be the maximum-tolerated radiation 
dose in radioimmunotherapy.23'25 Assuming the bone mar­
row to be the dose-limiting organ, doses as high as 200 
mCi l3lI-cG250 can be administered safely. Thus radia- 
tion-absorbed doses close to tumor-sterilizing levels seem 
achievable. Furthermore, single high-dose radioimmuno­
therapy with bone marrow support or multiple dosing, 
either with or without bone marrow support, may be nec­
essary to achieve major responses. With both approaches, 
considerable higher radioactivity doses can be adminis­
tered,19,26
In conclusion, cG250 seems to be a good candidate for 
radioimmunotherapy of RCC. The highly reduced immu­
nogenicity opens the possibility of multiple-treatment 
therapy. Further studies with cG250 are warranted to in­
vestigate whether this approach will lead to an effective 
therapy for patients with metastasized RCC.
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